Alicia Subasinghe

Washington, District of Columbia, United States
Alicia Subasinghe, Senior Director, Patient Advocacy, joined Cerevel in 2021. Cerevel is a clinical stage neuroscience company dedicated to unraveling the mysteries of the brain. As the head of the patient advocacy function, Alicia leads the development of enterprise-wide strategies for patient engagement across the lifecycle, working in close partnership with the patient community.

Prior to joining Cerevel, Alicia worked on the U.S. public affairs team at Novartis, where she led advocacy engagement with a broad set of organizations on federal and state policy issues. Alicia spent nearly a decade at the Pharmaceutical Research and Manufacturers of America (PhRMA) in both alliance development and public policy roles. Alicia led the association’s advocacy on a number of key drug development topics, including PDUFA VI, rare disease, and pediatric drug development. Earlier in her career, Alicia served in the U.S. government at the Office of Management and Budget (OMB) and the Office of the United States Trade Representative (USTR).

Alicia currently serves as the co-chair of the BIO Alliance Development Committee. Previously, Alicia served on the Nominating Committee of the National Health Council (NHC) and was co-chair of the National Organization of Rare Disorders’ (NORD) Federal Committee.

Alicia holds a M.A. in International Relations and International Economics from the Johns Hopkins Paul H. Nitze School of Advanced International Studies (SAIS) and a B.A. cum laude in Government & Politics with honors and Spanish Language & Literature from the University of Maryland at College Park.
Speaking In
2:45 PM - 3:30 PM (EDT)
Wednesday, October 27
This session will explore how to best navigate the delicate balance between patient advocacy groups…